title: Depression in later life: an overview with treatment recommendations.
abstract: We have already entered a new, more exciting, and hopeful era in the treatment of late-life depression. The increasing numbers of older adults who are surviving to more advanced ages and the greater recognition of late-life depression’s prevalence and impact on quality of life emphasize how important it is to detect and treat this disorder. Our increasing repertoire of evidence-based psychotherapeutic, pharmacologic, and neurotherapeutic treatment interventions offers many treatment alternatives, allowing substantial individualization of treatment approach. Demonstration of the effectiveness of depression treatment in primary care suggests the feasibility of increasing our patients’ access to care. Growing appreciation of the pathophysiology of depression and its interrelationships with cognitive impairment may increase our ability to limit or delay certain aspects of cognitive impairment through more aggressive treatment of depression. Improved recognition and treatment of late-life depression holds great potential for improving physical and mental health in later life, reducing disability in later years, and improving quality of life.
authors.affiliation: Geriatric Psychiatry Program, SB322, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA. jellison1@partners.org
authors.forename: James M
authors.initials: JM
authors.lastname: Ellison
authors.forename: Helen H
authors.initials: HH
authors.lastname: Kyomen
authors.forename: David G
authors.initials: DG
authors.lastname: Harper
mesh_terms: D000367:Age Factors; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000145:classification* / Q000494:pharmacology / Q000627:therapeutic use; D003072:Cognition Disorders / Q000150:complications / Q000523:psychology; D003704:Dementia / Q000150:complications* / Q000523:psychology; D003866:Depressive Disorder / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D015577:Geriatric Assessment / Q000379:methods*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000503:physiopathology; D011320:Primary Health Care; D011569:Psychiatric Status Rating Scales
chemical_list: D000928:Antidepressive Agents